PROTECT RCT DATA UPDATE

Results from the 1-Year Data Set
May 2024



The NaturalVue PROTECT Randomized Clinical Trial Delivers Outstanding Results in Myopia Correction and Protection

New Results:

Distribution of Change in Axial Length (mm) in Patients



58% of patients wearing NaturalVue had axial growth similar to age-matched emmetropic children

Wearing Time/Compliance

Compliance is believed to be essential for myopia control success and is influenced by the quality of vision and comfort.[1]

- Children wore NaturalVue for 11-12 hours per day
  - Similar to the control group, (single vision lenses) and greater than study protocol (10 hours/day, 6 days/week)
  - These longer wearing times indicate that vision and comfort were acceptable to children and strongly supported compliance.
  - The compliance factor for children is the PROTECT study is a contributor to the strong efficacy results reported.

PROTECT RCT

The Results
(1-Year Data Set)
New Data:

Distribution of Change in Refractive Error (D) in Patients



45% of patients had no progression (change < = 0 D)

≈2/3 of patients or 64% experienced no meaningful progression of myopia (defined as -0.25 D or less of progression)

Refractive Error

71%
0.41 D

Average reduction in refractive error progression

- The average refractive error reduction was 71%, or 0.41 D vs. control group for year one.

0.17 D

Average refractive error change

- Children wearing NaturalVue Multifocal showed an average refractive error change of 0.17 D.

Axial Length

0.17 MM
61%

Average reduction in axial elongation

- The average axial length reduction was 0.17 mm (61%) vs. control group for year one.

0.11MM

Average axial length change

- The average axial length change in children wearing NaturalVue Multifocal was 0.11 mm.

- Published real-world data indicates Year 2 myopia progression data **likely to trend closely** with Year 1 values.
- Combined with the 6-year data previously published in Clinical Ophthalmology in 2022, and the analysis from 3 independent studies released in September, the one-year data suggests NaturalVue Multifocal may **effectively manage eye growth and refractive error change among children under diverse clinical settings and populations.**

Note: This reflects the 1-year data set. The PROTECT study is ongoing and the data will continue to be reviewed and analyzed with additional details to be shared as available.
This information may describe uses for this product, i.e., Myopia Progression Control, which have not been approved by the FDA for use in the United States and is intended for educational purposes only. NaturalVue® Multifocal is part of an ongoing clinical trial (RCT) that is studying its effectiveness for myopia progression control.

1. Bullimore M, Jong M, Brennan N. Myopia control: Seeing beyond efficacy. , Optom Vis Sci 2024; 101:134-142

VTI-RCT-FS1 r4

PROTECT RCT